zoledronic acid has been researched along with Carcinoma, Non-Small Cell Lung in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (27.45) | 29.6817 |
| 2010's | 27 (52.94) | 24.3611 |
| 2020's | 10 (19.61) | 2.80 |
| Authors | Studies |
|---|---|
| Artioli, F; Bongiovanni, A; Burgio, MA; Fantini, M; Fausti, V; Foca, F; Forcignanò, MR; Guadalupi, V; Ibrahim, T; Menis, J; Mercatali, L; Miserocchi, A; Recine, F; Spadazzi, C; Stucci, SL | 1 |
| Chen, YY; Ding, ZY; Fu, Y; Wang, PP; Zheng, Y | 1 |
| Aerxiding, P; Aosiman, A; Liu, J; Nuermaimaiti, G; Yuan, M | 1 |
| Hu, Z; Li, W; Ruan, Y; Tian, Y; Zeng, F | 1 |
| Cruz, C; Miyashita, H; Smith, C | 1 |
| Ebisudani, T; Hosoi, A; Ikemura, S; Kakimi, K; Karasaki, T; Kawada, I; Kitano, K; Kobayashi, Y; Manabe, T; Masuzawa, K; Matsushita, H; Nagaoka, K; Nagayama, K; Nakajima, J; Nakamura, Y; Sato, M; Soejima, K; Suzuki, R; Takehara, T; Yasuda, H | 1 |
| Nachar, VR; Qin, A; Schepers, AJ; Tam, AH | 1 |
| Chen, D; Chen, X; Han, Y; Zang, X; Zhang, X; Zhou, J | 1 |
| Ebata, T; Ishiwata, T; Iwasawa, S; Saito, G; Takiguchi, Y; Tatsumi, K; Yoshino, I | 1 |
| Bian, W; Du, Y; Gao, Y; Huang, C; Liu, H; Liu, Q; Wan, L; Yang, X | 1 |
| Igishi, T; Izumi, H; Kodani, M; Makino, H; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yamaguchi, K; Yamasaki, A; Yanai, M | 1 |
| Aoyagi, T; Ichimura, S; Mochizuki, K; Morii, T; Ohnishi, H; Ohtsuka, K; Satomi, K; Tajima, T; Yoshiyama, A | 2 |
| Song, Z; Zhang, Y | 1 |
| Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T | 1 |
| Caraglia, M; De Rosa, G; Desiderio, V; Gazzano, E; Ghigo, D; Giordano, A; Kopecka, J; Lusa, S; Porto, S; Riganti, C; Salzano, G | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Feng, C; Guo, F; Huang, C; Li, X; Liu, X; Qin, Q; Wang, Y | 1 |
| Cserepes, M; Dobos, J; Hegedűs, B; Horváth, O; Izsák, V; Kenessey, I; Kói, K; Molnár, D; Tímár, J; Tóvári, J | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Udagawa, H; Umemura, S; Yoh, K | 1 |
| Chen, HQ; He, WZ; Li, ZM; Liao, ML; Lu, S; Wang, JJ; Xiang, JQ; Zhang, J; Zhou, XY; Zhou, Z | 1 |
| Ariyoshi, N; Hosoi, A; Kakimi, K; Kondo, M; Nakagawa, K; Nakajima, J; Noguchi, A; Sakuta, K; Sato, K; Sato, S; Shiraishi, K; Yoshida, Y | 1 |
| Chang, JW; Hsieh, JJ; Hsu, T; Li, YY; Shen, YC; Wang, CH; Yeh, KY | 1 |
| Argonza-Aviles, E; Ericson, SG; Gajra, A; Pandya, KJ; Warsi, GM; Wozniak, AJ | 1 |
| Boutsikou, E; Eleftheriadou, E; Kanakis, I; Karamanos, NK; Kontakiotis, T; Lithoxopoulou, H; Tzanakakis, G; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Hirsh, V; Langer, C | 1 |
| de Marinis, F; Ricciardi, S | 1 |
| Chen, WS; Hu, XY; Jin, C; Li, WD; Ma, L; Zou, QF | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Jahanzeb, M; Khan, R; Mahtani, R | 1 |
| Fukami, T; Kakimi, K; Matsushita, H; Murakawa, T; Murayama, T; Nakajima, J; Sakamoto, M; Takamoto, S; Yoshida, Y | 1 |
| Astone, A; Bagalà, C; Barone, C; Cassano, A; Di Salvatore, M; Orlandi, A; Quirino, M | 1 |
| Bargagli, G; Francini, E; Francini, F; Miano, ST; Pascucci, A; Petrioli, R; Ruggiero, G | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 1 |
| Calderone, R; Leary, A; Nimako, K; O'Brien, ME; Popat, S | 1 |
| Chung, K; Cong, Z; Danese, M; Dansey, R; Halperin, M; Henry, D; Qian, Y; Rader, M; Stopeck, A | 1 |
| Albert, I; Barbera, S; de Marinis, F; Engel-Riedel, W; Kosmidis, P; Kuo, HP; Manegold, C; Perez, JR; Sallo, V; Scagliotti, GV; Schallier, D; Schreurs, AJM | 1 |
| Gődény, M; Láng, I; Nagy, T; Rubovszky, G; Szász, A | 1 |
| Goto, K; Kubota, K; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K | 1 |
| Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
| Balakumaran, A; Ciuleanu, TE; García-Sáenz, JA; Henry, DH; Hirsh, V; Jacobs, I; Kanarev, V; Krzakowski, M; Lipton, L; Manegold, C; Mehta, ND; Pereira, JR; Prabhash, K; Rodriguez, G; Scagliotti, GV; Siena, S; Solal-Celigny, P; Wang, H; Woll, PJ | 1 |
| Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M | 1 |
| Price, N | 1 |
| De Souza, P; Gordon, D; Hirsh, V; Krzakowski, M; Pawlicki, M; Reitsma, D; Rosen, LS; Seaman, J; Tchekmedyian, NS; Urbanowitz, G; Yanagihara, R; Zheng, M | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Smith, M; Zheng, M | 1 |
| Hines, E; Tanvetyanon, T | 1 |
| Khuri, F; Saba, N | 2 |
| Avcu, F; Ural, AU | 1 |
| Chang, JW; Chou, WC; Huang, JS; Li, YY; Liaw, CC; Wang, CH; Wang, HM; Yeh, KY | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hirsh, V; Langer, CJ; Lipton, A; Major, PP; Smith, MR | 1 |
6 review(s) available for zoledronic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Humans; Randomized Controlled Trials as Topic; Strontium Radioisotopes; Survival Analysis; Zoledronic Acid | 2020 |
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Incidence; Lung Neoplasms; Neoplasm Metastasis; Zoledronic Acid | 2010 |
Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Practice Guidelines as Topic; Survival Analysis; Zoledronic Acid | 2009 |
The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2011 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Multicenter Studies as Topic; Nerve Compression Syndromes; Pain; Spinal Cord Compression; United States; Zoledronic Acid | 2005 |
14 trial(s) available for zoledronic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; Zoledronic Acid | 2020 |
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease-Free Survival; Docetaxel; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2014 |
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; United States; Zoledronic Acid | 2010 |
[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Peptides; Zoledronic Acid | 2010 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Male; Middle Aged; Neoplasm Staging; Quality of Life; T-Lymphocytes; Treatment Outcome; Zoledronic Acid | 2011 |
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid | 2011 |
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Calcium; Carcinoma, Non-Small-Cell Lung; Dietary Supplements; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2012 |
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Denosumab; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; RANK Ligand; Small Cell Lung Carcinoma; Survival Rate; Young Adult; Zoledronic Acid | 2012 |
Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Morbidity; Prognosis; Zoledronic Acid | 2004 |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Lung Neoplasms; Placebos; Zoledronic Acid | 2004 |
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Canada; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoclasts; Peptides; Retrospective Studies; Time Factors; Treatment Outcome; United States; Zoledronic Acid | 2008 |
31 other study(ies) available for zoledronic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Drug Synergism; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2021 |
Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cytokines; Immunologic Factors; Immunotherapy; Lung Neoplasms; Mice; Tumor Microenvironment; Zoledronic Acid | 2022 |
Zoledronic acid-associated osteonecro sis of the jaw in patients with EGFR-sensitive mutant lung cancer: two case reports.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Humans; Lung Neoplasms; Quality of Life; Zoledronic Acid | 2023 |
Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Musculoskeletal Abnormalities; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2021 |
Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Retrospective Studies; Zoledronic Acid | 2021 |
Dual-targeting tumor cells and tumor associated macrophages with lipid coated calcium zoledronate for enhanced lung cancer chemoimmunotherapy.
Topics: Calcium; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lipids; Lung Neoplasms; Macrophages; Male; Tumor Microenvironment; Tumor-Associated Macrophages; Zoledronic Acid | 2021 |
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2021 |
Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gefitinib; Humans; Janus Kinases; Lung Neoplasms; Mice; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays; Zoledronic Acid | 2021 |
Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Count; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; Retrospective Studies; Survival Analysis; T-Lymphocytes; Zoledronic Acid | 2018 |
Lung cancer cell line sensitivity to Zoledronic acid is BAX-dependent.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Imidazoles; Lung Neoplasms; RNA Interference; Zoledronic Acid | 2013 |
Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion, Malignant; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2014 |
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oxidative Stress; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Diphosphonates; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Humans; Imidazoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2017 |
Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; bcl-X Protein; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Incidence; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Peptides; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2008 |
Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunophenotyping; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; RNA; T-Lymphocytes; Zoledronic Acid | 2008 |
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Diphosphonates; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Organophosphonates; Quinazolines; Transplantation, Heterologous; Zoledronic Acid | 2009 |
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pain; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2009 |
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclins; Diphosphonates; G1 Phase; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Survivin; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Peptides; Periodontal Diseases; Radiography, Panoramic; Risk Factors; Tooth Extraction; Zoledronic Acid | 2011 |
Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Quality-Adjusted Life Years; United States; Zoledronic Acid | 2012 |
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diphosphonates; Humans; Hyperthermia, Induced; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Regeneration; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cohort Studies; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Peptides; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Zoledronic Acid | 2005 |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Time Factors; Zoledronic Acid | 2005 |
Radiosensitizing effect of zoledronic acid in small cell lung cancer.
Topics: Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Diphosphonates; Genes, ras; Humans; Imidazoles; Lung Neoplasms; Radiation-Sensitizing Agents; Signal Transduction; Zoledronic Acid | 2005 |
Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Flow Cytometry; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Microscopy, Phase-Contrast; Neoplasms, Experimental; Survival Rate; Treatment Outcome; Zoledronic Acid | 2008 |